Commodore Capital’s 89bio ETNB Stock Holding History

Commodore Capital’s Portfolio ETNB Stock Details ETNB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-758,244	Closed	-$9.65M	–	34
2022 Q4	$9.65M	Buy	+758,244	New	+$6.82M	1.45%	25

Other funds holding ETNB

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

Commodore Capital's ETNB Position: Q1 2023 in Review

Commodore Capital sold out of 89bio (ETNB) in Q1 2023, closing a stake of 758,244 shares — an estimated $9.65M sold.

Commodore Capital first reported a position in ETNB in Q4 2022 and held it in 1 quarter. The position peaked at $9.65M in Q4 2022. 145 funds tracked by Wall St. Rank hold ETNB as of Q1 2023.

Commodore Capital reported no remaining 89bio position as of Q1 2023 after selling out during the quarter.
Commodore Capital sold 758,244 89bio shares in Q1 2023, an estimated $9.65M.
Commodore Capital first reported a position in 89bio in Q4 2022 and held it in 1 quarter.
Commodore Capital's 89bio position peaked at $9.65M in Q4 2022.
145 funds tracked by Wall St. Rank held 89bio as of Q1 2023.

Based on Commodore Capital's 13F filing for Q1 2023, filed 15 May 2023.